Murayama Norie, Yajima Kanako, Hikawa Mikiko, Shimura Kanami, Ishii Yu, Takada Masaki, Uno Yasuhiro, Utoh Masahiro, Iwasaki Kazuhide, Yamazaki Hiroshi
Laboratory of Drug Metabolism and Pharmacokinetics, Showa Pharmaceutical University, Machida, Tokyo, 194-8543, Japan.
Pharmacokinetics and Bioanalysis Center, Shin Nippon Biomedical Laboratories, Ltd, Kainan, Wakayama, Japan.
Biopharm Drug Dispos. 2018 Feb;39(2):116-121. doi: 10.1002/bdd.2115. Epub 2017 Dec 21.
The fraction of substrate metabolized (f ) can be used to estimate drug interactions and can be determined by comparison of the intrinsic clearances (CL ) of victim drugs obtained from inhibited and uninhibited hepatic enzymes Commercially available human liver microsomes were recently developed in which one cytochrome P450 (P450) isoform is selectively inactivated. These inactivated liver microsomes were used to evaluate the roles of P450 2C isoforms in the depletion and oxidation of probe substrates. Determination of CL with sets of control and P450 2C9-inactivated liver microsomes yielded f values of 0.69-1.0 for celecoxib, diclofenac and warfarin. Apparent minor contributions of P450 1A2/2C8/3A4 were seen in depletion assays, yielding ~1 for the sum of the f values. Selectively inactivated liver microsomes were thereby shown to be potentially useful for determining the in vitro f values for major P450 2C9 contributions to substrate oxidations. Metabolite formations from diclofenac and warfarin were suppressed by 62-84% by the replacement of control liver microsomes with P450 2C9-inactivated liver microsomes. R-, S- and racemic omeprazole and troglitazone oxidation activities by liver microsomes at multiple substrate concentrations were suppressed by 26-36% and 22-50%, respectively, when P450 2C19- and 2C8-inactivated liver microsomes were used in place of control liver microsomes. This study provides important information to help elucidate the different roles of P450 isoforms in metabolite formation at different substrate concentrations. The data obtained allow the fractions metabolized to be calculated for victim drugs.
被代谢的底物分数(f)可用于估计药物相互作用,并且可以通过比较从受抑制和未受抑制的肝酶获得的受影响药物的内在清除率(CL)来确定。最近开发了市售的人肝微粒体,其中一种细胞色素P450(P450)同工型被选择性灭活。这些灭活的肝微粒体用于评估P450 2C同工型在探针底物消耗和氧化中的作用。用对照和P450 2C9灭活的肝微粒体组测定CL,得到塞来昔布、双氯芬酸和华法林的f值为0.69 - 1.0。在消耗试验中,P450 1A2/2C8/3A4的明显贡献较小,f值总和约为1。因此,选择性灭活的肝微粒体被证明可能有助于确定主要P450 2C9对底物氧化的体外f值。用P450 2C9灭活的肝微粒体替代对照肝微粒体后,双氯芬酸和华法林的代谢物形成被抑制了62 - 84%。当使用P450 2C19和2C8灭活的肝微粒体替代对照肝微粒体时,肝微粒体在多个底物浓度下对R -、S -和外消旋奥美拉唑及曲格列酮的氧化活性分别被抑制了26 - 36%和22 - 50%。本研究提供了重要信息,有助于阐明P450同工型在不同底物浓度下代谢物形成中的不同作用。获得的数据允许计算受影响药物的代谢分数。